ME Therapeutics Holdings Inc. is a preclinical biotechnology company focused on developing cancer-fighting drugs in immuno-oncology. While it boasts a strong liquidity position with a current ratio of 6.12 and minimal debt (debt/equity of 0.05), its financial health is concerning due to negative ROE and ROA figures, indicating inefficiencies in generating returns. The market cap of $31.85M and a stagnant stock price suggest limited investor confidence, reflecting the challenges typical of early-stage biotech firms. Overall, while the company has solid liquidity, its profitability metrics raise red flags.
Loading financial metrics...
Company posted a loss of $-1.2M over the last year, representing Infinity% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $862K over the last year.
Fortress balance sheet: cash covers total debt 20×, providing significant financial flexibility.
Excellent liquidity with current ratio of 6.1x ensures operational stability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-FY (August 31, 2025)